Most powerful obesity drug yet: People lost up to 25% of weight in trial
A new Chinese-made weight-loss drug helped trial participants shed nearly 18 percent of their body weight in under a year, according to clinical trial results reported by the New York Post. The figure approaches results seen with injectable GLP-1 therapies such as Wegovy, positioning the compound as a significant entrant in the competitive obesity-treatment market. No details on dosage, safety, or regulatory status were provided in the available excerpt. Separately, medical experts remain divided over prescribing powerful GLP-1 drugs to young children despite growing childhood obesity concerns.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Clinical trial results suggest a Chinese-made weight-loss drug could help people shed nearly 18 percent of their body weight in under a year.
- ✓ Physicians are divided over the use of powerful GLP-1 drugs for young children despite agreement that more must be done to address childhood obesity.
What changed
The feed now includes a reported clinical trial result for a Chinese-made weight-loss drug showing nearly 18 percent body-weight reduction in under a year, where prior intelligence contained no new clinical data or trial outcomes.
Live updates
-
Chinese weight-loss drug trial shows nearly 18% body-weight reduction
A new Chinese-made weight-loss drug helped trial participants shed nearly 18 percent of their body weight in under a year, according to clinical trial results reported by the New York Post. The figure approaches results seen with injectable GLP-1 therapies such as Wegovy, positioning the compound as a significant entrant in the competitive obesity-treatment market. No details on dosage, safety, or regulatory status were provided in the available excerpt. Separately, medical experts remain divided over prescribing powerful GLP-1 drugs to young children despite growing childhood obesity concerns.
Why it matters
The obesity drug field has rapidly advanced through semaglutide, tirzepatide, and experimental retatrutide, with both injectable and oral formulations under development. Previous reporting found no new clinical data or trial updates in recent feeds, leaving the competitive landscape without fresh statistical confirmation. A near-18 percent weight-loss result would represent a meaningful data point if verified through peer-reviewed publication or regulatory filing.
What is confirmed
- Clinical trial results suggest a Chinese-made weight-loss drug could help people shed nearly 18 percent of their body weight in under a year.
- Physicians are divided over the use of powerful GLP-1 drugs for young children despite agreement that more must be done to address childhood obesity.
Still unconfirmed
- The Chinese drug produces bigger results than Wegovy.
What to watch next
- Peer-reviewed publication or full trial data for the Chinese weight-loss drug
- Regulatory filings or approval decisions for the Chinese compound
- Further clinical guidance on GLP-1 use in children
confidence 50%Sources used for this update (3)
- nypost.com — New Chinese weight-loss drug produces bigger results than Wegovy in under a year
- www.nytimes.com — Study Paves Way for GLP-1s for Young Children, but Some Doctors Are Uneasy
- medicalxpress.com — A cancer drug is being touted online as a way to grow taller—what you need to know
-
No New Clinical Trial Data Available for Obesity Therapies
Recent intelligence feeds contain no new clinical data or updates regarding obesity drug trials, metabolic treatments, or trial outcomes. Previous reporting established a competitive market for metabolic therapies including semaglutide, tirzepatide, and the experimental triple-agonist retatrutide, which features both injectable and oral formulations. Current feeds return only unrelated material concerning industrial engineering time standards, English grammar references, dictionary definitions, and the Milton J. Rubenstein Museum of Science and Technology. Consequently, no new statistics regarding patient weight loss or clinical results are available to update the ongoing evaluation of next-generation treatments.
Why it matters
Prior evidence tracked specific patient outcomes and mechanisms across diverse treatment populations using standard GLP-1 medicines and emerging combination programs. The current absence of matching source material leaves the status of ongoing clinical trials and regulatory timelines unrefreshed. Observers continue to monitor the competitive development of metabolic treatments as manufacturers explore expanded clinical indications for patients.
What is confirmed
- Previous reporting established a competitive market featuring injectable and oral formulations of metabolic treatments such as semaglutide, tirzepatide, and retatrutide.
What to watch next
- Publication of new clinical trial data regarding obesity treatments
- Updates on regulatory approvals for oral and injectable metabolic formulations
confidence 20%Sources used for this update (5)
- www.industrial-engineered.com — MOST - INDUSTRIAL ENGINEERING
- dictionary.cambridge.org — Most, the most, mostly - Grammar - Cambridge Dictionary
- dictionary.cambridge.org — MOST | English meaning - Cambridge Dictionary
- www.most.org — MOST
- en.wiktionary.org — most - Wiktionary, the free dictionary
-
GLP-1 Studies and Next-Gen Weight-Loss Trials Update
New evidence outlines the clinical data behind metabolic treatments, including semaglutide, tirzepatide, and the experimental triple-agonist retatrutide. While drugs like Zepbound and Wegovy have established a competitive market featuring both injectable and recently approved oral formulations, the next generation of therapies aims to expand clinical indications. Clinical trials now track specific patient outcomes across diverse treatment populations, evaluating mechanisms from standard GLP-1 medicines to emerging combination programs.
Why it matters
Obesity care has evolved beyond basic weight management into specialized cardiometabolic treatment. Landmark trials such as STEP, SURMOUNT, SELECT, FLOW, SUMMIT, ESSENCE, OASIS 4, ATTAIN-1, TRIUMPH, SURPASS, and CagriSema provide the evidence base for these therapies. Understanding the distinct mechanisms, doses, and study populations helps clinicians handle the expanding pharmacotherapy market.
What is confirmed
- Semaglutide, tirzepatide, oral GLP-1 medicines, and retatrutide have changed obesity and cardiometabolic treatment.
- Clinical trial evidence spans the STEP, SURMOUNT, SELECT, FLOW, SUMMIT, ESSENCE, OASIS 4, ATTAIN-1, TRIUMPH, SURPASS, and CagriSema programs.
What to watch next
- Results from the emerging CagriSema program
- Further data updates on retatrutide patient outcomes
confidence 90%Sources used for this update (3)
- www.onedaymd.com — GLP-1 Studies Explained: The Complete Evidence Guide (2026 ...
- withwonderandwhimsy.com — Does Retatrutide live up to the data? A look at 2026 patient ...
- www.noom.com — Peptides for Weight Loss: Best Options Now & New ... - Noom
-
Eli Lilly Zepbound Outperforms Wegovy in First Head-to-Head Trial
Eli Lilly's Zepbound beat Novo Nordisk's Wegovy in the first head-to-head weight-loss trial. While Zepbound and Mounjaro are approved for weight and diabetes management, Lilly's experimental triple-agonist retatrutide remains in Phase 3 testing. Retatrutide has shown weight reductions up to 28.7 percent in trials and is currently being studied for efficacy in patients with obstructive sleep apnea and knee osteoarthritis. The FDA has expanded the GLP-1 market to include oral options, approving oral Wegovy in December 2025 and the non-peptide Foundayo on April 1, 2026.
Why it matters
The obesity drug market is shifting from single-hormone targets to dual and triple-agonist treatments to increase weight loss. This competition involves a transition from injectable-only therapies to FDA-approved oral pills. Regulatory scrutiny has increased for non-approved compounded versions of these peptides.
What is confirmed
- Zepbound outperformed Wegovy in the first head-to-head trial comparing the two drugs.
- Retatrutide is currently in Phase 3 testing and is not approved for use.
- The FDA approved oral Wegovy in December 2025 and Foundayo on April 1, 2026.
- Tirzepatide is marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management.
- The FDA issued warning letters to telehealth compounders in March 2026 regarding non-approved GLP-1 products.
Still unconfirmed
- GLP-1 drugs may cause a type of nerve pain where light touch makes skin feel like it is on fire.
What to watch next
- Eli Lilly's regulatory application for retatrutide in the first quarter of 2027
- Clinical results for retatrutide regarding obstructive sleep apnea and knee osteoarthritis
confidence 95%Sources used for this update (5)
- pharmaphorum.com — Zepbound tops Wegovy in first head-to-head weight-loss trial
- onedaymd.aestheticsadvisor.com — GLP-1 Hub 2026: Approved Drugs, Pills vs Injections ...
- www.dailymail.com — The disturbing Mounjaro and Ozempic side effect that can make even the lightest touch feel like your skin is 'on fire'... and why doctors think your dose may be to bla…
- ctv.veeva.com — A Study of Retatrutide (LY3437943) in Participants Who Have ...
- impactwealth.org — Mounjaro Weight Loss Results: What the SURMOUNT Trials ...
-
Retatrutide Trials Show Record Weight Loss
Eli Lilly reports that its experimental weekly injection retatrutide delivers more than double the weight loss of Ozempic's highest approved dose, reaching reductions up to 28.7 percent in clinical trials. The triple-agonist treatment targets three hormone receptors simultaneously, improving blood sugar control and cardiovascular risk factors. Medical professionals caution that extreme weight reduction can lead to physical frailty, lost strength, and eating difficulties. The drug remains in late-stage clinical trials without general approval, with the manufacturer planning a regulatory application in the first quarter of 2027.
Why it matters
Current obesity treatments face limitations in maximum efficacy, prompting pharmaceutical development toward multi-receptor targets that drive significantly larger reductions in body mass. Retatrutide addresses three hormone receptors simultaneously to achieve these unprecedented clinical results. However, rapid and substantial weight drops raise distinct clinical challenges regarding muscle mass preservation and patient strength.
What is confirmed
- Eli Lilly reports its experimental weekly injection retatrutide delivered more than double the weight loss of Ozempic in a Phase 3 diabetes trial.
- Retatrutide is in late-stage clinical trials and is not yet approved for general use.
Still unconfirmed
- Retatrutide could be one of the strongest weight loss drugs ever developed.
What to watch next
- Eli Lilly filing for regulatory approval in the first quarter of 2027
- Further Phase 3 trial data releases regarding long-term safety and frailty risks
confidence 100%Sources used for this update (2)
- www.fox5vegas.com — New weight loss drug retatrutide could be one of the ...
- www.scrippsnews.com — Could this drug be the next Ozempic? Lilly reports dramatic ...
-
Eli Lilly's Retatrutide Outperforms Ozempic in Trial
Eli Lilly plans to apply for regulatory approval in the first quarter of 2027 after clinical trials showed its experimental weekly injection, retatrutide, delivered more than twice the weight loss of Ozempic's highest approved dose. The triple-agonist treatment targets three hormone receptors simultaneously, producing weight reductions up to 28.7 percent in Phase 3 trials while improving blood sugar control and cardiovascular risk factors. Meanwhile, medical professionals warn that extreme weight reduction can cause physical frailty, lost strength, and eating difficulties.
Why it matters
The obesity drug market is shifting toward combination treatments that target multiple hormone receptors to enhance efficacy. Eli Lilly's retatrutide competes directly against Novo Nordisk products like Ozempic and the experimental injection CagriSema, which has shown average weight reductions near 25 percent in late-stage trials. These next-generation medications aim to improve both metabolic function and cardiovascular outcomes for patients with diabetes and obesity.
What is confirmed
- Eli Lilly's retatrutide targets three hormone receptors at once.
- Retatrutide produced up to 28.7% weight loss in Phase 3 trials.
- Drugmaker Lilly expects to apply for FDA approval next year.
- Retatrutide is a weekly injection that mimics three hunger-regulating hormones.
- Novo Nordisk reported that its experimental injection CagriSema produced average weight reductions near 25 percent among women in a late-stage clinical trial analysis.
Still unconfirmed
- Regulatory applications for retatrutide are expected in the first quarter of 2027.
What to watch next
- Eli Lilly's formal regulatory application expected in the first quarter of 2027
- Further Phase 3 trial data regarding cardiovascular outcomes and side effects
confidence 95%Sources used for this update (7)
- www.healthspectra.com — Retatrutide: What Eli Lilly's New Weight Loss Drug Could Do
- www.biospace.com — Lilly’s retatrutide trounces Novo’s Ozempic in diabetes ...
- abcnews.com — Retatrutide provides double the weight loss of Ozempic, data ...
- nypost.com — Retatrutide delivers double the weight loss as Ozempic: study
- www.businessinsider.com — Retatrutide Vs Ozempic: Double the Weight Loss, Different ...
- www.everydayhealth.com — Retatrutide Helped People With Diabetes Lose Twice as Much ...
- note.com — It's not just about 'losing weight.' Explaining the true nature of GLP-1 and how to use it correctly, based on the latest research papers
-
Novo Nordisk Drug CagriSema Achieves 25% Weight Loss in Women
Novo Nordisk reports that its experimental injection CagriSema produced average weight reductions near 25 percent among women in a late-stage clinical trial analysis. Results broken down by menopausal status show premenopausal women lost 26.7 percent, perimenopausal women lost 24.8 percent, and postmenopausal women lost 23.1 percent. The therapy builds upon the company's existing Wegovy treatment by utilizing a combination approach to tackle obesity. Meanwhile, competing therapies such as Eli Lilly's retatrutide have demonstrated substantial weight reductions approaching 29 percent while improving blood sugar control. Medical professionals warn that excessive weight reduction can trigger frailty, lost strength, and eating difficulties.
Why it matters
The Phase III clinical trial data highlights intensifying competition in the market for next-stage obesity treatments. Novo Nordisk continues to build the evidentiary case for its leading investigational drug, though exploratory findings do not guarantee identical outcomes in routine medical practice. The developments underscore the race between major pharmaceutical companies to deliver higher efficacy through advanced multi-hormone mechanisms.
What is confirmed
- Novo Nordisk's CagriSema injection achieved average weight reductions near 25 percent in women during a phase 3 trial analysis.
- Premenopausal women lost 26.7 percent of weight, compared with 24.8 percent for perimenopausal and 23.1 percent for postmenopausal women.
- Eli Lilly's competing retatrutide trials show weight losses approaching 29 percent alongside improved blood sugar control.
- Doctors warn that signs of frailty, lost strength, and trouble eating indicate when weight loss goes too far.
Still unconfirmed
- Exploratory findings from the trial guarantee similar high efficacy outcomes in routine clinical practice.
What to watch next
- Commercial availability and regulatory filing updates for CagriSema
- Long-term safety data addressing potential frailty and muscle loss from high-efficacy weight loss drugs
confidence 95%Sources used for this update (6)
- www.indiatoday.in — New obesity drug shows 25% weight loss in women: How it ...
- www.medscape.com — Beyond the Scale: Weight-Loss Drugs Aren’t a Quick Fix
- www.fool.com — Novo's CagriSema Delivered 25% Weight Loss in Women. Could It ...
- finance.yahoo.com — Novo's New Obesity Drug Just Hit 25% Weight Loss in Women
- pharma.economictimes.indiatimes.com — Novo's CagriSema Delivers 25% Weight Loss in Women, Possible ...
- pharmaphorum.com — CagriSema helps women lose 25% of their weight in study
-
Novo Nordisk Drug CagriSema Shows 25% Weight Loss in Late-Stage Analysis
Novo Nordisk released new evidence on October 20, 2026, showing its experimental CagriSema injection achieves average weight reduction near 25 percent in women. The late-stage analysis builds on the company's existing Wegovy injection by targeting weight loss through a combination approach. While Eli Lilly's competing triple-hormone agonist retatrutide has also demonstrated substantial weight reductions approaching 25 to 28 percent in trials and improves blood sugar control, Novo Nordisk's recent Phase III clinical trial data highlights intensifying competition in the market for next-generation obesity treatments.
Why it matters
Blockbuster weight loss treatments like Wegovy have dominated the market, prompting pharmaceutical companies to develop next-generation options with higher efficacy. Novo Nordisk and Eli Lilly are currently advancing competing candidates through late-stage trials to secure dominance in obesity care. These advanced therapies aim to push average weight reduction thresholds higher than previously possible with single-hormone medications.
What is confirmed
- Novo Nordisk released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.
- On October 20, 2026, Novo Nordisk announced promising results from a Phase III clinical trial of its new weight loss drug, CagriSema, which demonstrated a 25 percent average weight reduction in women.
Still unconfirmed
- An experimental drug that targets three metabolic pathways has shown promising results in people with type 2 diabetes helping them lose up to 15 percent of their body weight.
What to watch next
- Further regulatory updates and formal approval decisions regarding CagriSema and retatrutide.
- Additional Phase 3 clinical trial data releases from Novo Nordisk and Eli Lilly.
confidence 100%Sources used for this update (3)
- www.cnbc.com — Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis
- scitechdaily.com — New Triple-Action Drug Helps People With Diabetes Lose Up to ...
- www.gurufocus.com — CagriSema: Novo Nordisk's Promising Weight Loss Drug Shows 25 ...
-
Eli Lilly Retatrutide Phase 3 Trials Show Weight Loss Near 28%
Retatrutide, a triple-hormone receptor agonist from Eli Lilly, showed significant weight reduction in Phase 3 clinical trials. Results from the largest trial indicate average weight loss approaching 25%, while other data suggests averages near 28%. The drug improves blood sugar control and is currently undergoing five positive Phase 3 trials. Despite these results, the medication lacks formal approval, though some unauthorized versions are available through unregulated channels. Common side effects include nausea and diarrhea.
Why it matters
This drug targets three different hormone receptors to manage obesity and type 2 diabetes. It represents a progression in metabolic research beyond existing GLP-1 medications. Peer-reviewed papers have now been published on the findings.
What is confirmed
- Eli Lilly conducted clinical trials for retatrutide that resulted in significant weight reduction.
- Phase 3 trial results show average weight reductions approaching 25% in one of the largest studies.
- Retatrutide improves blood sugar control.
Still unconfirmed
- Average weight loss reached near 28% in the largest Phase 3 trial.
- Five positive Phase 3 trials have been completed.
What to watch next
- Formal regulatory approval status from health authorities
- Publication of additional peer-reviewed research papers
confidence 90%Sources used for this update (4)
- arstechnica.com — Beth Mole
- www.newsweek.com — When Could Reta Be Available? Weight-Loss Drug Retatrutide ...
- thepeptideinstitute.org — Retatrutide phase 3 results are in. Here is what the TRIUMPH ...
- www.thecompoundedit.com — Retatrutide: The Latest Clinical Trial Results and What They ...
-
Retatrutide Phase 3 Trials Show Up to 25 Percent Weight Loss
Experimental triple-hormone receptor agonist retatrutide demonstrates substantial weight loss in Phase 3 clinical trials, with adults with obesity losing up to 25 percent of their body weight over 80 weeks compared to a placebo. Participants with obesity and type 2 diabetes achieved an average weight loss of 18.8 percent on the highest dose over the same 80-week period. While the medication improves blood sugar control and aids weight management, trials also indicate side effects such as nausea and diarrhea. Although the drug lacks formal approval, unauthorized versions are already circulating through unregulated channels.
Why it matters
Retatrutide sets itself apart from single-hormone treatments like semaglutide and dual-hormone therapies like tirzepatide by activating three distinct hormone receptors at once. Recent broad meta-analyses of phase 3 trials indicate that the significant blood pressure reductions seen across modern obesity medications are largely driven by the physical weight loss itself. These developments arrive as regulatory scrutiny intensifies over gray-market distribution of unapproved peptide drugs.
What is confirmed
- Adults with obesity but no diabetes lost up to 25 percent of body weight on weekly retatrutide over 80 weeks compared to 3.9 percent on placebo.
- Adults with obesity and type 2 diabetes lost an average of 18.8 percent of their body weight on the highest dose of experimental retatrutide in an 80-week late-stage trial.
- Participants receiving a placebo alongside the diabetes trial lost an average of 5.1 percent over the same 80 weeks.
- Retatrutide is an experimental once-weekly injection that activates GLP-1, GIP, and glucagon receptors.
- A meta-analysis of 37 phase 3 trials involving more than 50,000 adults finds that weight loss explains about 76 percent of the blood-pressure reduction achieved with GLP-1 receptor agonists and multi-hormone receptor modulators.
Still unconfirmed
- Some companies are already widely distributing and selling retatrutide alongside other unregulated peptides despite the drug lacking official approval anywhere.
What to watch next
- Official regulatory submissions and formal review decisions for retatrutide approval.
- Further safety and efficacy data releases concerning black-market distribution of unapproved peptides.
- Additional findings on dosage titration charts ranging from 2 mg to 12 mg.
confidence 100%Sources used for this update (15)
- www.speedtest.net — Speedtest by Ookla - The Global Broadband Speed Test
- www.speedtest.net — Speedtest di Ookla - Il test globale per la velocità della tua...
- intelligence.speedtest.net — Speedtest Intelligence
- ciscoconnect.speedtest.net — Speedtest.net
- beta.speedtest.net — Speedtest for Windows:Windows用のインターネット速度テスト
- scitechdaily.com — Beyond Ozempic? New Weight Loss Drug Shows Stunning Results ...
- jen.jiji.com — Resinovich case, Visintin: "Only mud against me, expert report proves I am innocent"
- Bioengineer.org — Obesity Drugs Lower Blood Pressure Mostly by Shedding Pounds, Landmark Analysis Finds
- medicalxpress.com — Triple-action drug retatrutide delivers major weight loss for ...
- www.insidermonkey.com — Novo Nordisk’s Growth Story Is Under Pressure as Eli Lilly Gains Ground
- gizmodo.com — The Most Powerful Weight Loss Drug Yet Isn’t Approved, but ...
- fitnesshealthandnutrition.com — Retatrutide: 25% Weight Loss at 80 Weeks in Phase 3 Trial
-
Retatrutide shows up to 25% weight loss in clinical trials
Retatrutide, a triple-hormone receptor agonist for obesity, has shown significant weight loss results in clinical trials. Patients with obesity and type 2 diabetes lost up to 25% of their body weight, with some studies reporting average weight loss of 20-24.2%. The drug targets GLP-1, GIP, and glucagon receptors to improve blood sugar control and lower inflammation.
Why it matters
Obesity is a complex disease that affects millions worldwide, and current treatments often have limited efficacy. Retatrutide's promising results have generated excitement in the medical community, with some viewing it as a potential leap forward in managing obesity. The drug's mechanism of action, targeting multiple hormone receptors, may offer advantages over existing treatments.
What is confirmed
- Retatrutide produced 25% average weight loss at 80 weeks in the TRIUMPH-1 trial.
- Participants who received 12 mg of retatrutide for 80 weeks lost 20.8 percent of their body weight in the TRIUMPH-2 study.
- Retatrutide leads to nearly triple the weight loss of other treatments in the same time period.
- The drug targets GLP-1, GIP, and glucagon receptors to improve blood sugar control and lower inflammation.
What to watch next
- Phase 3 clinical trial results
- FDA approval decision
- market launch and pricing
confidence 90%Sources used for this update (13)
- knowridge.com — This Drug Helps Cut Weight and Blood Sugar - knowridge.com
- jen.jiji.com — Export, Strozzi: "We are studying other Innovits in the main global tech hubs"
- www.theedadvocate.org — Dramatic: This New Drug Helps 1 in 3 Lose 25% Body Weight ...
- glp3planner.com — Retatrutide Results: 24% Weight Loss in 48 Weeks (Trial Data)
- knowridge.com — New Drug Combo Helps People Lose Up to 23% of Body Weight
- greatergood.com — Microdosing Ozempic Is Going Viral as Users Chase Weight Loss With Smaller Doses and Fewer Side Effects
- businessdailymedia.com — Triple agonist UBT251 delivers up to 19.7% mean weight loss ...
- www.biospace.com — Obesity - BioSpace
- jen.jiji.com — Milan, waiter takes a photo of Fedez in a nightclub and is attacked by bouncers: investigations underway
- pepsreview.com — Retatrutide TRIUMPH-1 Results Published: Phase 3 Data Confirm ...
- www.zmescience.com — New Weight-Loss Drug Helps People With Type 2 Diabetes Lose 21% of Their Body Weight
- www.womenshealthmag.com — A New, Stronger GLP-1 Is Currently in Clinical Trials. Here's ...
-
Eli Lilly Retatrutide Enters Phase 3 Clinical Trials
Eli Lilly is advancing retatrutide, a triple-hormone receptor agonist for obesity, into Phase 3 clinical trials. Previous data showed patients with obesity and type 2 diabetes lost an average of 20-23.3% of their body weight, with some reaching 25% weight loss. The drug targets GLP-1, GIP, and glucagon receptors to improve blood sugar control and lower inflammation. Medical professionals view the drug as a potential leap forward in managing obesity as a complex disease.
Why it matters
Retatrutide differs from earlier weight loss drugs by targeting three distinct hormone receptors instead of one or two. This triple-action mechanism aims to provide more significant weight reduction and metabolic improvement.
What is confirmed
- Eli Lilly developed retatrutide as a triple-hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors.
- Patients with type 2 diabetes and obesity in trials lost an average of 20-23.3% of their body weight.
- Some trial participants lost up to 25% of their body weight.
Still unconfirmed
- Retatrutide could end obesity for good.
What to watch next
- Publication of Phase 3 clinical trial efficacy and safety data.
- Regulatory filing and approval decisions from health authorities.
confidence 90%Sources used for this update (2)
- www.thetechedvocate.org — This New Triple-Action Jab Could End Obesity for Good
- jen.jiji.com — Ovarian cancer, patients: "Drug reimbursed but access test not for everyone"
-
Eli Lilly's retatrutide shows up to 25% weight loss in trials
Eli Lilly's experimental obesity drug retatrutide has shown significant weight loss results in clinical trials, with patients losing up to 25% of their body weight. The drug, a triple-hormone receptor agonist, targets GLP-1, GIP, and glucagon receptors. In trials, patients with type 2 diabetes and obesity lost an average of 20-23.3% of their body weight. The drug also improved blood sugar control and reduced inflammation.
Why it matters
The obesity drug market is highly competitive, with several pharmaceutical companies developing new treatments. Retatrutide's promising results could make it a leading contender. Obesity is a major public health concern, with limited treatment options available. Effective treatments could have significant impacts on patients' health and quality of life.
What is confirmed
- Retatrutide is a triple-hormone obesity drug simulating GLP-1, GIP, and glucagon.
- Patients lost up to 25% of their body weight in trials.
- The drug improved blood sugar control and reduced inflammation.
- Retatrutide targets three metabolic receptors: GLP-1, GIP, and glucagon.
- Patients with type 2 diabetes and obesity lost an average of 20-23.3% of their body weight.
Still unconfirmed
- Eli Lilly's retatrutide could be submitted to the FDA for approval early next year.
What to watch next
- FDA approval decision
- Phase 3 trial results publication
- Comparative trials with other obesity drugs
confidence 95%Sources used for this update (18)
- Ars Technica — Most powerful obesity drug yet: People lost up to 25% of weight in trial
- The Guardian — ‘Godzilla’ of weight-loss drugs could provide other important health benefits
- Reuters — Lilly's experimental drug cuts weight by 21% in diabetes trial
- Scientific American — Blockbuster retatrutide trial signals a ‘new high-water mark’ for weight-loss drugs
- NBC News — People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug
- www.theguardian.com — ‘Godzilla’ of weight-loss drugs could provide other important ...
- arstechnica.com — Most powerful obesity drug yet: People lost up to 25% of ...
- www.everydayhealth.com — Retatrutide Led to Significant Weight Loss in Newly Published Diabetes Trial - Everyday Health
- medicalxpress.com — New investigational drug delivers up to 23.3% weight loss in people with obesity and diabetes
- time.com — Eli Lilly’s Experimental Weight-Loss Drug Shows Promising Results
- www.prnewswire.com — Lilly's triple agonist, retatrutide, delivered substantial ...
- www.fool.com — Lilly Just Reported More Than Half of Patients on Its New ...
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community